NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024 and June 27, 2025, both dates inclusive (the “Class Period”), of the important October 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on October 14, 2025 [1]. Group 1: Class Action Details - Investors who bought Unicycive securities between March 29, 2024, and June 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - The lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Unicycive made false or misleading statements regarding its ability to meet FDA manufacturing compliance requirements and the regulatory prospects of its New Drug Application for oxylanthanum carbunate [5]. - The claims suggest that these misrepresentations led to investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm has announced the filing of a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities during the specified Class Period, alleging misleading statements regarding the company's compliance with FDA requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025 [1]. - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbunate New Drug Application [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by October 14, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities, alleging misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 29, 2024, and June 27, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Unicycive overstated its readiness to meet FDA requirements and the prospects of its oxylanthanum carbunate New Drug Application [5]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Unicycive Therapeutics, Inc. securities, alleging misleading statements regarding the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for securities purchased between March 29, 2024, and June 27, 2025 [1]. - Investors who purchased Unicycive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that Unicycive's readiness to meet FDA manufacturing compliance was overstated, along with the regulatory prospects of its oxylanthanum carbunate New Drug Application [5]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by October 14, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of shareholders who purchased securities during the specified class period, alleging that the company misled investors regarding its business operations [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [3]. - It is alleged that the regulatory prospects of the oxylanthanum carbunate (OLC) New Drug Application (NDA) were also overstated [3]. - As a result of these misleading statements, investors reportedly suffered damages when the true details became public [3]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their motions with the court by October 14, 2025 [4]. - Participation in the class action is not required to be eligible for recovery; shareholders can remain absent class members if they choose [4]. Group 3: Rosen Law Firm Overview - Rosen Law Firm is recognized for its commitment to shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6].